CAR-T safe, effective for large B-cell lymphoma regardless of race or ethnicity

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.
Data from a real-world analysis revealed some disparities in objective and complete response rates but no statistically significant differences in measures of treatment durability for this chimeric antigen receptor T-cell therapy.
Thousands of patients with large B-cell lymphoma have been treated with axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead), often called axi-cel.

CHICAGO — Axicabtagene ciloleucel exhibited comparable efficacy and safety for large B-cell lymphoma regardless of patients’ race or ethnicity, according to study results presented at ASCO Annual Meeting.
Data from a real-world analysis revealed some disparities in objective and complete response rates but no statistically significant differences in measures of treatment durability for this chimeric antigen receptor T-cell therapy.
Thousands of patients with large B-cell lymphoma have been treated with axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead), often called axi-cel.